HBV News and Research

RSS

AGA issues six new clinical practice guidelines

In 2015, the American Gastroenterological Association issued six clinical practice guidelines, all published in AGA's official journal Gastroenterology, offering current, evidence-based point-of-care recommendations to guide physicians at the bedside.

17 Dec 2015

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus.

16 Dec 2015

HBsAg may persist in chronic HBV patients beyond seroclearance

The use of a highly sensitive assay for the detection of hepatitis B surface antigen suggests that HBsAg negativity as evaluated by the conventional test may not be indicative of seroclearance in patients with chronic hepatitis B virus infection.

3 Dec 2015

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial.

3 Dec 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

Hiroshima University researchers report promising new avenue for treating hepatitis B

A promising new avenue for treating hepatitis B has been reported by researchers at Hiroshima University who have developed a new animal model of the disease.

28 Oct 2015

Men on effective HIV therapy less likely to get HBV infection, shows research

Previous studies of individuals with HIV have suggested that HIV drug regimens that included drugs active against hepatitis B virus (HBV) can decrease the risk of infection with the liver-damaging HBV.

13 Oct 2015

HBV DNA levels guide antiviral treatment in chemotherapy setting

Pretreatment levels of hepatitis B virus DNA could inform the withdrawal of pre-emptive antiviral therapy in chronic HBV patients undergoing cytotoxic chemotherapy for cancer, indicate research findings published in Digestive Diseases and Sciences.

3 Sep 2015

Countrywide variations in chronic HBV burden revealed

A systematic review of the worldwide prevalence of chronic hepatitis B virus infection finds wide variation between countries.

3 Sep 2015

Risk score predicts ACLF risk in chronic HBV patients

A risk score incorporating routinely collected clinical information can identify patients with chronic hepatitis B virus infection at high risk of developing acute-on-chronic liver failure following severe acute exacerbation, research suggests.

3 Sep 2015

IP10 levels linked to HBsAg decline during TDF treatment

Baseline serum interferon-inducible protein 10 levels predict hepatitis B surface antigen reduction in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection treated with tenofovir disoproxil fumarate, findings indicate.

4 Aug 2015

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

Hepatitis B surface antigen level and platelet count at baseline are significantly associated with spontaneous HBsAg seroclearance in hepatitis B virus carriers and those with chronic infection, research suggests.

4 Aug 2015

Genotype A HBV mapped in acute, chronic Japanese patients

Not only is genotype A the most common genotype among Japanese patients with acute hepatitis B virus infection, but its prevalence is spreading among young adults with chronic HBV infection, shows a nationwide study.

4 Aug 2015

Kalorama Information: NGS diagnostics can detect any number of genetic variants

Next generation sequencing may be able to bypass some of the downside of molecular testing and in doing so earn its place in clinical testing, according to Kalorama Information.

30 Jun 2015

Hepatic ALT flares linked to HBsAg clearance

Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers.

30 Jun 2015

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut.

30 Jun 2015

New book examines all aspects of HBV and HDV infections

Despite the availability of an effective vaccine for hepatitis B, hundreds of millions of people worldwide are infected with the hepatitis B virus (HBV). This virus can cause serious liver damage and cancer in chronically infected patients. Hepatitis delta virus (HDV), a satellite of HBV, can exacerbate the disease.

19 Jun 2015

Beckman Coulter brings new thinking to new lab challenges at EuroMedLab 2015

Beckman Coulter Diagnostics supports IFCC-EFLM EuroMedLab 2015 with a showcase of solutions to improve workflow for the diagnostics laboratory. Held from 22-24 June 2015 at the Paris Palais des Congrès France, the company demonstrates its dedication to moving the clinical diagnostic lab forward with its total laboratory solution—from automation, chemistry, immunoassay and haematology to microbiology and its new molecular diagnostics system.

From Beckman Coulter Diagnostics 18 Jun 2015

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.

3 Jun 2015

Telbivudine drug prevents perinatal transmission of HBV

The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a study in the June issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

2 Jun 2015